Lessons From COVID-19 for Pandemic Preparedness : Proceedings From a Multistakeholder Think Tank
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches to prepare for the next pandemic. In May 2022, the Duke Clinical Research Institute convened a think tank with thought leaders from academia, clinical practice, the pharmaceutical industry, patient advocacy, the National Institutes of Health, the US Food and Drug Administration, and the Centers for Disease Control and Prevention to share, firsthand, expert knowledge of the insights gained from the COVID-19 pandemic and how this acquired knowledge can help inform the next pandemic response. The think tank focused on pandemic preparedness, therapeutics, vaccines, and challenges related to clinical trial design and scale-up during the early phase of a pandemic. Based on the multi-faceted discussions, we outline 10 key steps to an improved and equitable pandemic response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 77(2023), 12 vom: 15. Dez., Seite 1635-1643 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Narayanasamy, Shanti [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 01.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad418 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359368107 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359368107 | ||
| 003 | DE-627 | ||
| 005 | 20240401232324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad418 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM359368107 | ||
| 035 | |a (NLM)37435958 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Narayanasamy, Shanti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lessons From COVID-19 for Pandemic Preparedness |b Proceedings From a Multistakeholder Think Tank |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches to prepare for the next pandemic. In May 2022, the Duke Clinical Research Institute convened a think tank with thought leaders from academia, clinical practice, the pharmaceutical industry, patient advocacy, the National Institutes of Health, the US Food and Drug Administration, and the Centers for Disease Control and Prevention to share, firsthand, expert knowledge of the insights gained from the COVID-19 pandemic and how this acquired knowledge can help inform the next pandemic response. The think tank focused on pandemic preparedness, therapeutics, vaccines, and challenges related to clinical trial design and scale-up during the early phase of a pandemic. Based on the multi-faceted discussions, we outline 10 key steps to an improved and equitable pandemic response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a emergency use authorization | |
| 650 | 4 | |a warm clinical infrastructure | |
| 700 | 1 | |a Curtis, Lesley H |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Adrian F |e verfasserin |4 aut | |
| 700 | 1 | |a Woods, Christopher W |e verfasserin |4 aut | |
| 700 | 1 | |a Moody, M Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Sulkowski, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Turbett, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Baden, Lindsey R |e verfasserin |4 aut | |
| 700 | 1 | |a Gulick, Roy M |e verfasserin |4 aut | |
| 700 | 1 | |a Pau, Alice K |e verfasserin |4 aut | |
| 700 | 1 | |a Adam, Stacey J |e verfasserin |4 aut | |
| 700 | 1 | |a Marks, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Stockbridge, Norman L |e verfasserin |4 aut | |
| 700 | 1 | |a Dobbins, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Krofah, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Leav, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Phil |e verfasserin |4 aut | |
| 700 | 1 | |a Roessig, Lothar |e verfasserin |4 aut | |
| 700 | 1 | |a Vedin, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Waldstreicher, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Berman, Stacey Cromer |e verfasserin |4 aut | |
| 700 | 1 | |a Cremisi, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Schofield, Lesley |e verfasserin |4 aut | |
| 700 | 1 | |a Gandhi, Rajesh T |e verfasserin |4 aut | |
| 700 | 1 | |a Naggie, Susanna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 77(2023), 12 vom: 15. Dez., Seite 1635-1643 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:1635-1643 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad418 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2023 |e 12 |b 15 |c 12 |h 1635-1643 | ||